Novartis agreed to purchase biotechnology firm Avidity in a deal valued at $12 billion, making it the Swiss drugmaker’s largest acquisition in additional than a decade and including a number of potential blockbuster therapies as generic competitors looms for its present top-sellers. Sam Fazeli of Bloomberg Intelligence has extra.
——–
Extra on Bloomberg Tv and Markets
Like this video? Subscribe and activate notifications so you do not miss any movies from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Go to http://www.bloomberg.com for enterprise information & evaluation, up-to-the-minute market information, options, profiles and extra.
Join with Bloomberg Tv on:
X: https://twitter.com/BloombergTV
Fb: https://www.fb.com/BloombergTelevision
Instagram: https://www.instagram.com/bloombergtv/
Join with Bloomberg Enterprise on:
X: https://twitter.com/enterprise
Fb: https://www.fb.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/
TikTok: https://www.tiktok.com/@bloombergbusiness?lang=en
Reddit: https://www.reddit.com/r/bloomberg/
LinkedIn: https://www.linkedin.com/firm/bloomberg-news/
Extra from Bloomberg:
Bloomberg Radio: https://twitter.com/BloombergRadio
Bloomberg Surveillance: https://twitter.com/bsurveillance
Bloomberg Politics: https://twitter.com/bpolitics
Bloomberg Originals: https://twitter.com/bbgoriginals
Watch extra on YouTube:
Bloomberg Expertise: https://www.youtube.com/@BloombergTechnology
Bloomberg Originals: https://www.youtube.com/@enterprise
Bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake
Bloomberg Espanol: https://www.youtube.com/@bloomberg_espanol
Bloomberg Podcasts: https://www.youtube.com/@BloombergPodcasts
